RT Journal Article
SR Electronic
T1 Ribosome Phenotypes Enable Rapid Antibiotic Susceptibility Testing in Escherichia coli
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.18.24309111
DO 10.1101/2024.06.18.24309111
A1 Farrar, Alison
A1 Turner, Piers
A1 Sayyed, Hafez El
A1 Feehily, Conor
A1 Chatzimichail, Stelios
A1 Crook, Derrick
A1 Andersson, Monique
A1 Oakley, Sarah
A1 Barrett, Lucinda
A1 Nellåker, Christoffer
A1 Stoesser, Nicole
A1 Kapanidis, Achillefs N.
YR 2024
UL http://medrxiv.org/content/early/2024/06/20/2024.06.18.24309111.abstract
AB Rapid antibiotic susceptibility tests (ASTs) are an increasingly important part of clinical care as antimicrobial resistance (AMR) becomes more common in bacterial infections. Here, we use the spatial distribution of fluorescently labelled ribosomes to detect intracellular changes associated with antibiotic susceptibility in single E. coli cells using a convolutional neural network (CNN). By using ribosome-targeting probes, a single fluorescence cell image provides data for cell segmentation and susceptibility phenotyping. Using 50,722 images of cells from an antibiotic-susceptible laboratory strain of E. coli, we showed that antibiotics with different mechanisms of action result in distinct ribosome phenotypes, which can be identified by a CNN with high accuracy (99%, 96%, and 91% for ciprofloxacin, gentamicin, and chloramphenicol). With 6 E. coli strains isolated from bloodstream infections, we used 34,205 images of ribosome phenotypes to train a CNN that could classify susceptible cells with 92% accuracy and resistant cells with 99% accuracy. Such accuracies correspond to the ability to differentiate susceptible and resistant samples with 99% confidence with just 2 cells, meaning that this method could eliminate lengthy sample culturing steps and could determine in vitro susceptibility with 30 minutes of antibiotic treatment. Our ribosome phenotype method should also be able to identify phenotypes in other strains and species.Competing Interest StatementThe work was carried out using a wide-field microscope from Oxford Nanoimaging, a company in which A.N.K. is a co-founder and shareholder. A.N.K. received no payment for this work from Oxford Nanoimaging, and Oxford Nanoimaging was not involved in any aspect of this work.Funding StatementThis work was supported by the Oxford Martin School (by the establishment of the Oxford Martin School Programme on Antimicrobial Resistance Testing; to A.N.K., N.S., C.N., D.C. and M.A.), by Wellcome Trust grant 110164/Z/15/Z (to A.N.K.), by the Clarendon Fund Scholarships (to A.F.), and by UK Biotechnology and Biological Sciences Research Council grants BB/N018656/1 and BB/S008896/1 (to A.N.K.). The research was additionally supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance (NIHR200915) at the University of Oxford in partnership with United Kingdom Health Security Agency (UKHSA) and by the NIHR Oxford Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR, the Department of Health or Public Health England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the use of clinical isolates processed by the John Radcliffe Hospital microbiology laboratory in the development of diagnostic assays was granted by the UK's Health Research Authority (London - Queen Square Research Ethics Committee [REC reference: 17/LO/1420]).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes